Shamila D. Alipoor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shamila D. Alipoor has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Johan Garssen
Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands
11 shared publications - Esmaeil Mortaz
Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
7 shared publications - Mehdi Mirsaeidi
Division of Pulmonology & Critical Care, Department of Internal Medicine, Dell Medical School, The University of Texas, Austin, USA
6 shared publications - Mohammad Varahram
Mycobacteriology Research Center (MRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
6 shared publications Esmaeil Mortaz
Department of Immunology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 shared publicationsIan M. Adcock
Priority Research Centre for Asthma and Respiratory Disease, Hunter Medical Research Institute, University of Newcastle, Newcastle, NSW, Australia
5 shared publications
Latest Publications
- Open Access
Maternal and Neonatal Immune Signatures at Birth and Future Type 1 Diabetes: Potential Antiviral and Inflammatory Immune Profiles
Background/Objectives: Prenatal immune programming may contribute to the development of type 1 diabetes (T1D), but the maternal and neonatal immune profiles associated with subsequent disease remain poorly understood. This study aims to investigate maternal and neonatal serum proteomic signatures and cord blood DNA methylation patterns in relation to future T1D. Methods: We analyzed maternal serum proteomic profiles collected at delivery, neonatal cord serum proteomic profiles, and cord blood DNA methylation data from mothers and children in the ABIS birth cohort. Results: After false discovery rate (FDR) correction, 60 maternal proteins, but only 3 neonatal proteins, differed significantly between the T1D and control groups. Both proteomic analyses showed enrichment of immune and inflammatory pathways, with Th1/Th2, Th17, IL-17, and chemokine signaling additionally enriched in neonatal serum. In a further analysis restricted to virus-annotated KEGG pathways, the enriched pathways in both datasets converged on shared immune and inflammatory signaling components and did not indicate infection with a specific pathogen. Network integration identified shared immune hubs, including TNF, CD40LG, and multiple CCL/CXCL chemokines. Cord blood DNA methylation changes were modest, although nominally significant differentially methylated genes (DMGs) were associated with immune-related and host–pathogen interaction pathways, showing biological convergence with the proteomic findings. Conclusion: Maternal and neonatal immune profiles at birth may reflect inflammatory processes associated with subsequent T1D development. Maternal serum proteomics provided stronger statistical evidence, whereas the neonatal findings were hypothesis-generating. Further studies in larger independent cohorts, including targeted protein assays, are needed to validate these findings and clarify their biological significance.
Open AccessMaternal and Neonatal Immune Signatures at Birth and Future Type 1 Diabetes: Potential Antiviral and Inflammatory Immune Profiles
Background/Objectives: Prenatal immune programming may contribute to the development of type 1 diabetes (T1D), but the maternal and neonatal immune profiles associated with subsequent disease remain poorly understood. This study aims to investigate maternal and neonatal serum proteomic signatures and cord blood DNA methylation patterns in relation to future T1D. Methods: We analyzed maternal serum proteomic profiles collected at delivery, neonatal cord serum proteomic profiles, and cord blood DNA methylation data from mothers and children in the ABIS birth cohort. Results: After false discovery rate (FDR) correction, 60 maternal proteins, but only 3 neonatal proteins, differed significantly between the T1D and control groups. Both proteomic analyses showed enrichment of immune and inflammatory pathways, with Th1/Th2, Th17, IL-17, and chemokine signaling additionally enriched in neonatal serum. In a further analysis restricted to virus-annotated KEGG pathways, the enriched pathways in both datasets converged on shared immune and inflammatory signaling components and did not indicate infection with a specific pathogen. Network integration identified shared immune hubs, including TNF, CD40LG, and multiple CCL/CXCL chemokines. Cord blood DNA methylation changes were modest, although nominally significant differentially methylated genes (DMGs) were associated with immune-related and host–pathogen interaction pathways, showing biological convergence with the proteomic findings. Conclusion: Maternal and neonatal immune profiles at birth may reflect inflammatory processes associated with subsequent T1D development. Maternal serum proteomics provided stronger statistical evidence, whereas the neonatal findings were hypothesis-generating. Further studies in larger independent cohorts, including targeted protein assays, are needed to validate these findings and clarify their biological significance.
- Open Access
The SKP2–Substrate Axis in Hematological Malignancies: Mechanisms of Oncogenesis and Opportunities for Targeted Therapy
S-phase kinase-associated protein 2 (SKP2), a key substrate-recognition subunit of the Skp1-Cul1-F-box (SCF) E3 ubiquitin ligase complex, promotes the ubiquitin–proteasome-mediated degradation of tumor suppressors such as p27Kip1 and p21(Cip1/Waf1). Through these activities, SKP2 regulates critical cellular processes, including cell cycle progression, apoptosis, metabolic reprogramming, maintenance of cancer stem cell stemness, and contributes to the pathogenesis, therapeutic resistance, and clinical progression of hematological malignancies. Recent advances in protein degradation technologies and regulatory network analysis have highlighted SKP2 and its substrate interactions as promising targets for precision therapies. In this review, we examine the biological functions of SKP2 and regulatory mechanisms governing its substrate spectrum across hematological malignancies, including acute myeloid leukemia, chronic myeloid leukemia, B/NK/T-cell lymphoma, and multiple myeloma. We further review currently available SKP2-targeted therapeutic strategies, including small-molecule inhibitors, molecular glue degraders, and proteolysis-targeting chimeras (PROTACs), and discuss SKP2-related prognostic biomarkers in hematological malignancies. Finally, we outline the key challenges and future directions to guide the development of SKP2-centered therapeutic approaches.
Open AccessThe SKP2–Substrate Axis in Hematological Malignancies: Mechanisms of Oncogenesis and Opportunities for Targeted Therapy
S-phase kinase-associated protein 2 (SKP2), a key substrate-recognition subunit of the Skp1-Cul1-F-box (SCF) E3 ubiquitin ligase complex, promotes the ubiquitin–proteasome-mediated degradation of tumor suppressors such as p27Kip1 and p21(Cip1/Waf1). Through these activities, SKP2 regulates critical cellular processes, including cell cycle progression, apoptosis, metabolic reprogramming, maintenance of cancer stem cell stemness, and contributes to the pathogenesis, therapeutic resistance, and clinical progression of hematological malignancies. Recent advances in protein degradation technologies and regulatory network analysis have highlighted SKP2 and its substrate interactions as promising targets for precision therapies. In this review, we examine the biological functions of SKP2 and regulatory mechanisms governing its substrate spectrum across hematological malignancies, including acute myeloid leukemia, chronic myeloid leukemia, B/NK/T-cell lymphoma, and multiple myeloma. We further review currently available SKP2-targeted therapeutic strategies, including small-molecule inhibitors, molecular glue degraders, and proteolysis-targeting chimeras (PROTACs), and discuss SKP2-related prognostic biomarkers in hematological malignancies. Finally, we outline the key challenges and future directions to guide the development of SKP2-centered therapeutic approaches.
- Open Access
- 3 April 2026
- Published by Wiley in Journal of Internal Medicine
- Vol. 299 (6) , 670-693
Immune endotypes in tuberculosis: Keys to decoding disease complexity
Tuberculosis (TB) remains a major global health challenge, with multi‐drug antibiotic regimens as the current standard of care. While effective at killing Mycobacterium tuberculosis , these treatments do not resolve persistent inflammation, prevent lung damage, or reverse immune dysregulation that contribute to poor outcomes and disease recurrence. Precision medicine offers a promising alternative but requires deeper insight into disease mechanisms to enable tailored interventions. This comprehensive review introduces the concept of immune endotyping to define the underlying disease mechanisms as tools to decode clinical and immunological heterogeneity in TB. TB displays a wide spectrum of clinical phenotypes, from latent or asymptomatic infection to mild or severe disease with characteristic non‐cavitary or cavitary lung pathology. Instead, distinct immune endotypes capture the diverse biological pathways that shape disease progression and treatment response. Similar clinical presentations may arise from different immune dysfunctions, underscoring the need to move beyond broad phenotypic classifications. Advances in multi‐omics and computational analyses uncover immune signatures that enable stratification for host‐directed therapies (HDTs) targeting hyperinflammation, immunosuppression, coagulopathy or metabolic exhaustion. Integrating clinical, radiological, and immunological data through multimodal profiling is essential for developing personalized interventions. We also explore how endotyping has transformed treatment in other diseases, offering valuable insights for TB. Additionally, we present examples of how putative immune endotypes may be targeted with appropriate HDTs. In summary, this review underscores the potential of immune endotypes to advance precision medicine in TB, moving beyond one‐size‐fits‐all treatment to improve outcomes, especially in severe and drug‐resistant cases.
- 3 April 2026
- Published by Wiley in Journal of Internal Medicine
- Vol. 299 (6) , 670-693
Open AccessImmune endotypes in tuberculosis: Keys to decoding disease complexity
Tuberculosis (TB) remains a major global health challenge, with multi‐drug antibiotic regimens as the current standard of care. While effective at killing Mycobacterium tuberculosis , these treatments do not resolve persistent inflammation, prevent lung damage, or reverse immune dysregulation that contribute to poor outcomes and disease recurrence. Precision medicine offers a promising alternative but requires deeper insight into disease mechanisms to enable tailored interventions. This comprehensive review introduces the concept of immune endotyping to define the underlying disease mechanisms as tools to decode clinical and immunological heterogeneity in TB. TB displays a wide spectrum of clinical phenotypes, from latent or asymptomatic infection to mild or severe disease with characteristic non‐cavitary or cavitary lung pathology. Instead, distinct immune endotypes capture the diverse biological pathways that shape disease progression and treatment response. Similar clinical presentations may arise from different immune dysfunctions, underscoring the need to move beyond broad phenotypic classifications. Advances in multi‐omics and computational analyses uncover immune signatures that enable stratification for host‐directed therapies (HDTs) targeting hyperinflammation, immunosuppression, coagulopathy or metabolic exhaustion. Integrating clinical, radiological, and immunological data through multimodal profiling is essential for developing personalized interventions. We also explore how endotyping has transformed treatment in other diseases, offering valuable insights for TB. Additionally, we present examples of how putative immune endotypes may be targeted with appropriate HDTs. In summary, this review underscores the potential of immune endotypes to advance precision medicine in TB, moving beyond one‐size‐fits‐all treatment to improve outcomes, especially in severe and drug‐resistant cases.
- Open Access
Epigenetic Crosstalk Between BCG-Infected Macrophages and Naïve Monocytes Potentiates Antimycobacterial Activity
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a leading cause of death from infectious disease. Infected cells secrete extracellular vesicles (EVs), nanosized membrane-bound particles containing bioactive molecules known to mediate intercellular communication and influence immune regulation during infection. We hypothesized that EVs secreted from Mycobacterium bovis Bacillus Calmette Guérin (BCG)-infected macrophages could epigenetically reprogram naïve monocytes and enhance their mycobactericidal activity against Mtb. A transwell co-culture system was used to enable communication via EVs and soluble factors, between BCG-infected macrophages and naïve monocytes (recipient macrophages). To assess the impact of these factors, we examined epigenetic reprogramming and the ability to control Mtb growth. BCG-infected macrophages released EVs with a distinct proteomic profile mapping to multiple tuberculosis-related pathways. Recipient macrophages exhibited altered DNA methylation patterns compared to those co-cultured with untreated, Staphylococcus aureus -infected or hydrogen peroxide-exposed macrophages. The proteomic cargo of EVs and differentially methylated genes in recipient cells showed significant interactions with TNF as a central hub enriched in both the phagosome and tuberculosis pathway. The epigenetic reprogramming was accompanied by a trend towards improved control of Mtb in vitro . BCG infection induces release of EVs that, together with soluble factors, induce targeted epigenetic remodeling in recipient macrophages. In this study, we demonstrate that extracellular vesicles (EVs) released during Mycobacterium bovis -infection carry a directed proteomic cargo mapping to several tuberculosis-related pathways. Furthermore, we show that these proteins interact with differentially methylated genes in EV-recipient macrophages. Our findings indicate that infected macrophages transmit epigenetic information via EVs. This work provides new insights into intercellular and epigenetic mechanisms linked to innate immune memory.
Open AccessEpigenetic Crosstalk Between BCG-Infected Macrophages and Naïve Monocytes Potentiates Antimycobacterial Activity
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a leading cause of death from infectious disease. Infected cells secrete extracellular vesicles (EVs), nanosized membrane-bound particles containing bioactive molecules known to mediate intercellular communication and influence immune regulation during infection. We hypothesized that EVs secreted from Mycobacterium bovis Bacillus Calmette Guérin (BCG)-infected macrophages could epigenetically reprogram naïve monocytes and enhance their mycobactericidal activity against Mtb. A transwell co-culture system was used to enable communication via EVs and soluble factors, between BCG-infected macrophages and naïve monocytes (recipient macrophages). To assess the impact of these factors, we examined epigenetic reprogramming and the ability to control Mtb growth. BCG-infected macrophages released EVs with a distinct proteomic profile mapping to multiple tuberculosis-related pathways. Recipient macrophages exhibited altered DNA methylation patterns compared to those co-cultured with untreated, Staphylococcus aureus -infected or hydrogen peroxide-exposed macrophages. The proteomic cargo of EVs and differentially methylated genes in recipient cells showed significant interactions with TNF as a central hub enriched in both the phagosome and tuberculosis pathway. The epigenetic reprogramming was accompanied by a trend towards improved control of Mtb in vitro . BCG infection induces release of EVs that, together with soluble factors, induce targeted epigenetic remodeling in recipient macrophages. In this study, we demonstrate that extracellular vesicles (EVs) released during Mycobacterium bovis -infection carry a directed proteomic cargo mapping to several tuberculosis-related pathways. Furthermore, we show that these proteins interact with differentially methylated genes in EV-recipient macrophages. Our findings indicate that infected macrophages transmit epigenetic information via EVs. This work provides new insights into intercellular and epigenetic mechanisms linked to innate immune memory.
- Open Access
- 20 February 2025
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 68 (1) , 1-22
Immunomodulatory Significance of Mast Cell Exosomes (MC-EXOs) in Immune Response Coordination
Mast cells (MCs) communicate with other cells by direct cell-to-cell interaction, secreting mediators, and releasing exosomes (EXOs). MC-exosomes (MC-EXOs) contain proteins, lipids, mRNAs, and noncoding RNAs (ncRNAs), exhibit typical EXO markers such as heat shock proteins, tetraspanins, tumor susceptibility gene 101 protein (TSG101), and ALG-2-interacting protein X (ALIX), and are released constitutively or following MC degranulation. MC-EXOs also have signature MC markers like FcεRI and KIT (CD117), which allows for their identification and comparison with other EXO populations. Following their release, MC-EXOs may interact with the recipient cell(s) directly or be internalized and then release their protein and nucleic acid content. This may contribute to the regulation of immune responses and other biological processes and reprogramming of recipient cells. MC-EXO proteins may integrate and become a functional part of the recipient cell membrane. The mRNA transferred by MC-EXOs is functional and the transfer of exosomal RNA to other MCs results in the expression of donor MC proteins in the recipient MCs. Moreover, MCs may function as the recipients of EXOs that are released by other non-immune and immune cells, altering the secretome of MCs. In this review, we focus on how MC-EXOs modulate the biology of other cells and vice versa; and we highlight the role of MC-EXOs in the pathogenesis of allergic and non-allergic diseases.
- 20 February 2025
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 68 (1) , 1-22
Open AccessImmunomodulatory Significance of Mast Cell Exosomes (MC-EXOs) in Immune Response Coordination
Mast cells (MCs) communicate with other cells by direct cell-to-cell interaction, secreting mediators, and releasing exosomes (EXOs). MC-exosomes (MC-EXOs) contain proteins, lipids, mRNAs, and noncoding RNAs (ncRNAs), exhibit typical EXO markers such as heat shock proteins, tetraspanins, tumor susceptibility gene 101 protein (TSG101), and ALG-2-interacting protein X (ALIX), and are released constitutively or following MC degranulation. MC-EXOs also have signature MC markers like FcεRI and KIT (CD117), which allows for their identification and comparison with other EXO populations. Following their release, MC-EXOs may interact with the recipient cell(s) directly or be internalized and then release their protein and nucleic acid content. This may contribute to the regulation of immune responses and other biological processes and reprogramming of recipient cells. MC-EXO proteins may integrate and become a functional part of the recipient cell membrane. The mRNA transferred by MC-EXOs is functional and the transfer of exosomal RNA to other MCs results in the expression of donor MC proteins in the recipient MCs. Moreover, MCs may function as the recipients of EXOs that are released by other non-immune and immune cells, altering the secretome of MCs. In this review, we focus on how MC-EXOs modulate the biology of other cells and vice versa; and we highlight the role of MC-EXOs in the pathogenesis of allergic and non-allergic diseases.
- Open Access
- 21 May 2024
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 14, 1398077
Significance of extracellular vesicles in orchestration of immune responses in Mycobacterium tuberculosis infection
Mycobacterium tuberculosis (M.tb), the causative agent of Tuberculosis, is an intracellular bacterium well known for its ability to subvert host energy and metabolic pathways to maintain its intracellular survival. For this purpose, the bacteria utilize various mechanisms of which extracellular vehicles (EVs) related mechanisms attracted more attention. EVs are nanosized particles that are released by almost all cell types containing active biomolecules from the cell of origin and can target bioactive pathways in the recipient cells upon uptake. It is hypothesized that M.tb dictates the processes of host EV biogenesis pathways, selectively incorporating its molecules into the host EV to direct immune responses in its favor. During infection with Mtb, both mycobacteria and host cells release EVs. The composition of these EVs varies over time, influenced by the physiological and nutritional state of the host environment. Additionally, different EV populations contribute differently to the pathogenesis of disease at various stages of illness participating in a complex interplay between host cells and pathogens. These interactions ultimately influence immune responses and disease outcomes. However, the precise mechanisms and roles of EVs in pathogenicity and disease outcomes remain to be fully elucidated. In this review, we explored the properties and function of EVs in the context of M.tb infection within the host microenvironment and discussed their capacity as a novel therapeutic strategy to combat tuberculosis.
- 21 May 2024
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 14, 1398077
Open AccessSignificance of extracellular vesicles in orchestration of immune responses in Mycobacterium tuberculosis infection
Mycobacterium tuberculosis (M.tb), the causative agent of Tuberculosis, is an intracellular bacterium well known for its ability to subvert host energy and metabolic pathways to maintain its intracellular survival. For this purpose, the bacteria utilize various mechanisms of which extracellular vehicles (EVs) related mechanisms attracted more attention. EVs are nanosized particles that are released by almost all cell types containing active biomolecules from the cell of origin and can target bioactive pathways in the recipient cells upon uptake. It is hypothesized that M.tb dictates the processes of host EV biogenesis pathways, selectively incorporating its molecules into the host EV to direct immune responses in its favor. During infection with Mtb, both mycobacteria and host cells release EVs. The composition of these EVs varies over time, influenced by the physiological and nutritional state of the host environment. Additionally, different EV populations contribute differently to the pathogenesis of disease at various stages of illness participating in a complex interplay between host cells and pathogens. These interactions ultimately influence immune responses and disease outcomes. However, the precise mechanisms and roles of EVs in pathogenicity and disease outcomes remain to be fully elucidated. In this review, we explored the properties and function of EVs in the context of M.tb infection within the host microenvironment and discussed their capacity as a novel therapeutic strategy to combat tuberculosis.
- Open Access
- 26 July 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1239739
Editorial: Exosomes and exosomal miRNAs as biomarkers in infection with Mycobacterium tuberculosis
Editorial: Exosomes and exosomal miRNAs as biomarkers in infection with Mycobacterium tuberculosis
- 26 July 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1239739
Open AccessEditorial: Exosomes and exosomal miRNAs as biomarkers in infection with Mycobacterium tuberculosis
Editorial: Exosomes and exosomal miRNAs as biomarkers in infection with Mycobacterium tuberculosis
- Open Access
Exosomal miRNAs in the Tumor Microenvironment of Multiple Myeloma
Multiple myeloma (MM) is a malignancy of plasma cells in the bone marrow and is characterized by the clonal proliferation of B-cells producing defective monoclonal immunoglobulins. Despite the latest developments in treatment, drug resistance remains one of the major challenges in the therapy of MM. The crosstalk between MM cells and other components within the bone marrow microenvironment (BME) is the major determinant of disease phenotypes. Exosomes have emerged as the critical drivers of this crosstalk by allowing the delivery of informational cargo comprising multiple components from miniature peptides to nucleic acids. Such material transfers have now been shown to perpetuate drug-resistance development and disease progression in MM. MicroRNAs(miRNAs) specifically play a crucial role in this communication considering their small size that allows them to be readily packed within the exosomes and widespread potency that impacts the developmental trajectory of the disease inside the tumor microenvironment (TME). In this review, we aim to provide an overview of the current understanding of the role of exosomal miRNAs in the epigenetic modifications inside the TME and its pathogenic influence on the developmental phenotypes and prognosis of MM.
Open AccessExosomal miRNAs in the Tumor Microenvironment of Multiple Myeloma
Multiple myeloma (MM) is a malignancy of plasma cells in the bone marrow and is characterized by the clonal proliferation of B-cells producing defective monoclonal immunoglobulins. Despite the latest developments in treatment, drug resistance remains one of the major challenges in the therapy of MM. The crosstalk between MM cells and other components within the bone marrow microenvironment (BME) is the major determinant of disease phenotypes. Exosomes have emerged as the critical drivers of this crosstalk by allowing the delivery of informational cargo comprising multiple components from miniature peptides to nucleic acids. Such material transfers have now been shown to perpetuate drug-resistance development and disease progression in MM. MicroRNAs(miRNAs) specifically play a crucial role in this communication considering their small size that allows them to be readily packed within the exosomes and widespread potency that impacts the developmental trajectory of the disease inside the tumor microenvironment (TME). In this review, we aim to provide an overview of the current understanding of the role of exosomal miRNAs in the epigenetic modifications inside the TME and its pathogenic influence on the developmental phenotypes and prognosis of MM.
- 26 June 2022
- Published by Springer Nature in Molecular Biology Reports
- Vol. 49 (11) , 10715-10727
SARS-CoV-2 cell entry beyond the ACE2 receptor
Background Angiotensin-converting enzyme 2 (ACE2) is known as the major viral entry site for SARS-CoV-2. However, viral tissue tropism and high rate of infectivity do not directly correspond with the level of ACE2 expression in the organs. It may suggest involvement of other receptors or accessory membrane proteins in SARSCoV-2 cell entry. Methods and Results A systematic search was carried out in PubMed/Medline, EMBASE, and Cochrane Library for studies reporting SARS-CoV-2 cell entry. We used a group of the MeSH terms including “cell entry”, “surface receptor”, “ACE2”, and “SARS-CoV-2”. We reviewed all selected papers published in English up to end of February 2022. We found several receptors or auxiliary membrane proteins (including CD147, NRP-1, CD26, AGTR2, Band3, KREMEN1, ASGR1, ANP, TMEM30A, CLEC4G, and LDLRAD3) along with ACE2 that facilitate virus entry and transmission. Expression of Band3 protein on the surface of erythrocytes and evidence of binding with S protein of SARS-CoV-2 may explain asymptomatic hypoxemia during COVID19 infection. The variants of SARS-CoV-2 including the B.1.1.7 (Alpha), B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.617.2+ (Delta+), and B.1.1.529 (Omicron) may have different potency to bond with these receptors. Conclusions The high rate of infectivity of SARS-CoV-2 may be due to its ability to enter the host cell through a group of cell surface receptors. These receptors are potential targets to develop novel therapeutic agents for SARS-CoV-2. Graphical abstract
- 26 June 2022
- Published by Springer Nature in Molecular Biology Reports
- Vol. 49 (11) , 10715-10727
SARS-CoV-2 cell entry beyond the ACE2 receptor
Background Angiotensin-converting enzyme 2 (ACE2) is known as the major viral entry site for SARS-CoV-2. However, viral tissue tropism and high rate of infectivity do not directly correspond with the level of ACE2 expression in the organs. It may suggest involvement of other receptors or accessory membrane proteins in SARSCoV-2 cell entry. Methods and Results A systematic search was carried out in PubMed/Medline, EMBASE, and Cochrane Library for studies reporting SARS-CoV-2 cell entry. We used a group of the MeSH terms including “cell entry”, “surface receptor”, “ACE2”, and “SARS-CoV-2”. We reviewed all selected papers published in English up to end of February 2022. We found several receptors or auxiliary membrane proteins (including CD147, NRP-1, CD26, AGTR2, Band3, KREMEN1, ASGR1, ANP, TMEM30A, CLEC4G, and LDLRAD3) along with ACE2 that facilitate virus entry and transmission. Expression of Band3 protein on the surface of erythrocytes and evidence of binding with S protein of SARS-CoV-2 may explain asymptomatic hypoxemia during COVID19 infection. The variants of SARS-CoV-2 including the B.1.1.7 (Alpha), B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.617.2+ (Delta+), and B.1.1.529 (Omicron) may have different potency to bond with these receptors. Conclusions The high rate of infectivity of SARS-CoV-2 may be due to its ability to enter the host cell through a group of cell surface receptors. These receptors are potential targets to develop novel therapeutic agents for SARS-CoV-2. Graphical abstract
- Open Access
Inborn Errors in the LRR Domain of Nod2 and Their Potential Consequences on the Function of the Receptor
The innate immune system plays a critical role in the early detection of pathogens, primarily by relying on pattern-recognition receptor (PRR) signaling molecules. Nucleotide-binding oligomerization domain 2 (NOD2) is a cytoplasmic receptor that recognizes invading molecules and danger signals inside the cells. Recent studies highlight the importance of NOD2′s function in maintaining the homeostasis of human body microbiota and innate immune responses, including induction of proinflammatory cytokines, regulation of autophagy, modulation of endoplasmic reticulum (ER) stress, etc. In addition, there is extensive cross-talk between NOD2 and the Toll-like receptors that are so important in the induction and tuning of adaptive immunity. Polymorphisms of NOD2′s encoding gene are associated with several pathological conditions, highlighting NOD2′s functional importance. In this study, we summarize NOD2′s role in cellular signaling pathways and take a look at the possible consequences of common NOD2 polymorphisms on the structure and function of this receptor.
Open AccessInborn Errors in the LRR Domain of Nod2 and Their Potential Consequences on the Function of the Receptor
The innate immune system plays a critical role in the early detection of pathogens, primarily by relying on pattern-recognition receptor (PRR) signaling molecules. Nucleotide-binding oligomerization domain 2 (NOD2) is a cytoplasmic receptor that recognizes invading molecules and danger signals inside the cells. Recent studies highlight the importance of NOD2′s function in maintaining the homeostasis of human body microbiota and innate immune responses, including induction of proinflammatory cytokines, regulation of autophagy, modulation of endoplasmic reticulum (ER) stress, etc. In addition, there is extensive cross-talk between NOD2 and the Toll-like receptors that are so important in the induction and tuning of adaptive immunity. Polymorphisms of NOD2′s encoding gene are associated with several pathological conditions, highlighting NOD2′s functional importance. In this study, we summarize NOD2′s role in cellular signaling pathways and take a look at the possible consequences of common NOD2 polymorphisms on the structure and function of this receptor.